Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update

Expert Review of Molecular Diagnostics

Volumn 16, Issue 8, 2016, Pages 897-913

  Ghosh, Nilanjana ^a   Dutta, Mainak ^a   Singh, Brajesh ^a   Banerjee, Rintu ^a   Bhattacharyya, Parthasarathi ^b   Chaudhury, Koel ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b Institute of Pulmocare and Research   (India)

Author keywords

biomarkers; COPD; lipidomics; metabolomics; metabonomics; omics; proteomics; transcriptomics

Indexed keywords

BIOLOGICAL MARKER;

BLOOD SAMPLING; BODY FLUID; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; EPITHELIAL LINING FLUID; EXHALED BREATH CONDENSATE; HIGH RISK POPULATION; HUMAN; LUNG PARENCHYMA; MEDLINE; METABOLOMICS; NON INVASIVE PROCEDURE; PERSONALIZED MEDICINE; PHENOTYPE; PROTEOMICS; REVIEW; SPUTUM ANALYSIS; TRANSCRIPTOMICS; URINALYSIS; CASE CONTROL STUDY; COMORBIDITY; GENE EXPRESSION PROFILING; GENETICS; LUNG; METABOLISM; PROCEDURES; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY;

BIOMARKERS; BODY FLUIDS; CASE-CONTROL STUDIES; COMORBIDITY; GENE EXPRESSION PROFILING; HUMANS; LUNG; METABOLOMICS; PROGNOSIS; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS;

EID: 84979295891     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1198258     Document Type: Review

References (111)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. [updated 2010; cited 2016 Jan10]. Available from: www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf•• This document is of considerable interest as it defines COPD, states problems about diagnosis, and also talks about possible treatments as accepted globally.
2. World Health Organization. Chronic respiratory diseases. Burden of COPD. [cited 2016 Jan10]. Available from: www.who.int/respiratory/copd/burden/en/
3. N.G.Csikesz, E.J.Gartman New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 2014;9:277–286.
4. H.Chen, X.Wang. Significance of bioinformatics in research of chronic obstructive pulmonary disease. J Clin Bioinforma. 2011;1:35.• This review paper is important as it stresses on the integrative understanding of COPD using omics and systems biology.
5. W.M.Caudle, T.K.Bammler, Y.Lin, et al. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother. 2010;10:925–942.
6. T.Janvilisri. Omics-based identification of biomarkers for nasopharyngeal carcinoma. Dis Markers. 2015;2015:762128.
7. G.Baggerman, E.Vierstraete, A.De Loof, et al. Gel-based versus gel-free proteomics: a review. Comb Chem High Throughput Screen. 2005;8:669–677.
8. W.J.Griffiths. Metabolomics, metabonomics and metabolite profiling. Cambridge: RSC Publishing; 2008.
9. Z.Pan, D.Raftery. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 2007;387:525–527.
10. P.Soininen, A.J.Kangas, P.Würtz, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134:1781–1785.
11. Z.Wang, M.Gerstein, M.Snyder. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57–63.
12. A.Comandini, P.Rogliani, A.Nunziata, et al. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respir Med. 2009;103:1592–1613.
13. V.Pinto-Plata, J.Toso, K.Lee, et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc. 2006;3:465–466.
14. C.E.Wheelock, V.M.Goss, D.Balgoma, et al. Application of ’omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013;42:802–825.•• This is a pioneering review paper defining the concept of omics technologies explaining the principles, limitations, and work done in each of the platforms in inflammatory lung diseases.
15. P.Scherp, G.Ku, L.Coleman, et al. Gel-based and gel-free proteomic technologies. Methods Mol Biol. 2011;702:163–190.• An important paper focusing on the various tools available for proteome analysis with the advantages and disadvantages of each.
16. M.Frantzi, A.Bhat, A.Latosinska. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014;3:7.•• This review paper stresses on the several checkpoints between the different phases of discovery, verification, and validation of proteomic biomarkers before the establishment of valid biomarkers.
17. K.Chandramouli, P.-Y.Qian, et al. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics. 2009;2009:1–22.
18. N.M.Verrills, J.A.Irwin, X.Y.He, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1633–1643.
19. G.S.J.B.Rana, T.P.York, J.S.Edmiston, et al. Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Anal Bioanal Chem. 2010;397:1809–1819.
20. S.Merali, C.A.Barrero, R.P.Bowler, et al. Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. Copd. 2014;11:177–189.
21. B.Nicholas, R.Djukanović. Induced sputum: a window to lung pathology. Biochem Soc Trans. 2009;37:868–872.
22. G.Pelaia, R.Terracciano, A.Vatrella, et al. Application of proteomics and peptidomics to COPD. Biomed Res Int. 2014;2014:1–8.
23. M.D.Pastor, A.Nogal, S.Molina-Pinelo, et al. Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics. 2013;89:227–237.
24. B.L.Nicholas, P.Skipp, S.Barton, et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:1049–1060.
25. S.Ohlmeier, W.Mazur, A.Linja-Aho, et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J Proteome Res. 2012;11:599–608.
26. J.Gao, S.Ohlmeier, P.Nieminen, et al. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study. Am J Physiol Lung Cell Mol Physiol. 2015;309:L17–L26.
27. R.Terracciano, M.Preianò, G.P.Palladino, et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics. 2011;11:3402–3414.
28. B.Titz, A.Sewer, T.Schneider, et al. Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. J Proteomics. 2015;128:306–320.
29. J.N.Baraniuk, B.Casado, L.K.Pannell, et al. Protein networks in induced sputum from smokers and COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1957–1975.
30. G.M.Mutlu, K.W.Garey, R.A.Robbins, et al. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001;164:731–737.
31. M.Griese, J.Noss, C.von Bredow. Protein pattern of exhaled breath condensate and saliva. Proteomics. 2002;2:690–696.
32. B.Casado, M.Luisetti, P.Iadarola, et al. Advances in proteomic techniques for biomarker discovery in COPD. Expert Rev Clin Immunol. 2011;7:111–123.
33. R.P.Bowler, M.C.Ellison, N.Reisdorph. Proteomics in pulmonary medicine. Chest. 2006;130:567–574.• One of the first review papers summarizing all work in proteomics in pulmonary diseases.
34. M.Fumagalli, F.Ferrari, M.Luisetti, et al. Profiling the proteome of exhaled breath condensate in healthy smokers and COPD patients by LC-MS/MS. Int J Mol Sci. 2012;13:13894–13910.
35. J.A.Bartlett, M.E.Albertolle, C.Wohlford-Lenane, et al. Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs. Am J Physiol Lung Cell Mol Physiol. 2013;305:L256–L266.
36. E.Kipnis, K.Hansen, T.Sawa, et al. Proteomic analysis of undiluted lung epithelial lining fluid. Chest. 2008;134:338–345.
37. D.Merkel, W.Rist, P.Seither, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics. 2005;5:2972–2980.
38. R.Terracciano, G.Pelaia, M.Preianò, et al. Asthma and COPD proteomics: current approaches and future directions. Proteomics Clin Appl. 2015;9:203–220.
39. L.Franciosi, N.Govorukhina, F.Fusetti, et al. Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. Electrophoresis. 2013;34:2683–2694.
40. L.Franciosi, D.S.Postma, M.van den Berge, et al. Susceptibility to COPD: differential proteomic profiling after acute smoking. PLoS One. 2014;9:e102037.
41. B.Magi, E.Bargagli, L.Bini, et al. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics. 2006;6:6354–6369.
42. R.Savino, S.Paduano, M.Preianò, et al. The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci. 2012;13:13926–13948.
43. C.Tu, M.J.Mammen, J.Li, et al. Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J Proteome Res. 2014;13:627−629.
44. H.Chen, D.Wang, C.Bai, et al. Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res. 2010;9:2798–2808.
45. S.G.Kelsen, X.Duan, R.Ji, et al. Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. Am J Respir Cell Mol Biol. 2008;38:541–550.
46. S.Ohlmeier, M.Vuolanto, T.Toljamo, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res. 2008;7:5125–5132.
47. E.J.Lee, K.H.In, J.H.Kim, et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest. 2009;135:344–352.
48. B.M.Alexandre, N.Charro, J.Blonder, et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics. 2012;76:259–269.
49. N.Ishikawa, S.Ohlmeier, K.Salmenkivi, et al. Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD. Respir Res. 2010;11:123.
50. S.Ohlmeier, P.Nieminen, J.Gao, et al. Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2016;310:L1155-L1165. doi:10.1152/ajplung.00021.2016.
51. J.K.Nicholson, J.C.Lindon, E.Holmes. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–1189.
52. J.C.Lindon, J.K.Nicholson. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:45–69.
53. J.K.Nicholson, J.C.Lindon. Systems biology: metabonomics. Nature. 2008;455:1054–1056.•• A pioneering paper on the concept and applications of metabonomics.
54. G.J.Patti, O.Yanes, G.Siuzdak. Metabolomics: the apogee of the omictriology. Nat Rev Mol Cell Biol. 2012;13:263–269.
55. G.D.Laurentiis, D.Paris, D.Melck, et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J. 2008;32:1175–1183.
56. G.D.Laurentiis, D.Paris, D.Melck, et al. Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. J Proteome Res. 2013;12:1502–1511.
57. J.L.Izquierdo-García, G.Peces-Barba, S.Heili, et al. Is NMR-based metabolomic analysis of exhaled breath condensate accurate? Eur Respir J. 2011;37:468–470.
58. M.Basanta, R.M.Jarvis, Y.Xu, et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 2010;135:315–320.
59. M.Basanta, B.Ibrahim, R.Dockry, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012;13:72.
60. N.Fens, S.B.de Nijs, S.Peters, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J. 2011;38:1301–1309.
61. J.L.McClay, D.E.Adkins, N.G.Isern, et al. (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res. 2010;9:3083–3090.
62. L.Wang, Y.Tang, S.Liu, et al. Metabonomic profiling of serum and urine by 1H NMR based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS One. 2013;8:e65675.
63. D.J.Adamko, P.Nair, I.Mayers, et al. Metabolomic profiling of asthma and chronic obstructive pulmonary disease: a pilot study differentiating diseases. J Allergy Clin Immunol. 2015;136:571–580.
64. A.Ząbek, I.Stanimirova, S.Deja, et al. Fusion of the (1)H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructive sleep apnea syndrome. Metabolomics. 2015;11:1563–1574.
65. B.K.Ubhi, J.H.Riley, P.A.Shaw, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40:345–355.
66. B.K.Ubhi, K.K.Cheng, J.Dong, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8:3125–3133.
67. S.Deja, I.Porebska, A.Kowal, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369–380.
68. M.Paige, M.D.Burdick, S.Kim, et al. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun. 2011;413:588–593.
69. Q.Chen, R.S.Deeb, Y.Ma, et al. Serum metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS One. 2015;10:e0143937.
70. E.D.Telenga, R.F.Hoffmann, R.t’Kindt, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am J Respir Crit Care Med. 2014;190:155–164.
71. R.P.Bowler, S.Jacobson, C.Cruickshank, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2015;191:275–284.
72. J.H.Malone, B.Oliver. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34.
73. D.Chaussabel, V.Pascual, J.Banchereau. Assessing the human immune system through blood transcriptomics. BMC Biol. 2010;8:84.• An important review discussing the field and applications of transcriptomics.
74. R.Almansa, L.Socias, M.Sanchez-Garcia, et al. Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes. BMC Res Notes. 2012;5:401.
75. T.M.Bahr, G.J.Hughes, M.Armstrong, et al. Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;49:316–323.
76. S.Grundy, J.Plumb, S.Lea, et al. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One. 2013;8:e71629.
77. M.E.P.Roberts, B.W.Higgs, P.Brohawn, et al. CD4+ T-cell profiles and peripheral blood ex-vivo responses to T-cell directed stimulation delineate COPD phenotypes. Chronic Obstr Pulm Dis (Miami). 2015;2:268–280.
78. A.H.Agler, R.G.Crystal, J.G.Mezey, et al. Differential expression of vitamin E and selenium-responsive genes by disease severity in chronic obstructive pulmonary disease. Copd. 2013;10:450–458.
79. W.J.Kim, J.H.Lim, J.S.Lee, et al. Comprehensive analysis of transcriptome sequencing data in the lung tissues of COPD subjects. Int J Genomics. 2015;2015:1–9.
80. R.Faner, T.Cruz, T.Casserras, et al. Network analysis of lung transcriptomics reveals a distinct B cell signature in emphysema. Am J Respir Crit Care Med. 2016;193:1242–1253.
81. D.Singh, S.M.Fox, R.Tal-Singer, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66:489–495.
82. D.K.Kim, M.H.Cho, C.P.Hersh, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:1238–1247.
83. S.J.Skates, M.A.Gillette, J.LaBaer, et al. Statistical design for biospecimen cohort size in proteomics based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–5394.
84. A.P.Diz, M.Truebano, D.O.F.Skibinski. The consequences of sample pooling in proteomics: an empirical study. Electrophoresis. 2009;30:2967–2975.
85. C.Kendziorski, R.A.Irizarry, K.-S.Chen, et al. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA. 2005;102:4252–4257.
86. P.Müller, G.Parmigiani, C.Robert, et al. Optimal sample size for multiple testing. J Am Stat Assoc. 2004;99:990–100.
87. R.Tibshirani. A simple method for assessing sample sizes in microarray experiments. BMC Bioinformatics. 2006;7:106.
88. P.Liu, J.T.G.Hwanga. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics. 2007;23:739–746.
89. W.-J.Lin, H.-M.Hsueh, J.J.Chen. Power and sample size estimation in microarray studies. BMC Bioinformatics. 2010;11:48.
90. G.Nyamundanda, I.C.Gormley, Y.Fan, et al. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics. 2013;14:338.
91. J.Xia, I.V.Sinelnikov, B.Han, et al. MetaboAnalyst 3.0––making metabolomics more meaningful. Nucleic Acids Res. 2015;43:W251–W257.
92. W.Pan, J.Lin, C.T.Le. How many replicates of arrays are required to detect gene expression changes in microarray experiments? A mixture model approach. Genome Biol. 2002;3:research0022.
93. K.Dobbin, R.Simon. Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics. 2005;6:27–38.
94. Y.Pawitan, S.Michiels, S.Koscielny, et al. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005;21:3017–3024.
95. M.C.Yang, J.J.Yang, R.A.McIndoe, et al. Microarray experimental design: power and sample size considerations. Physiol Genomics. 2003;16:24–28.
96. W.Qiu, M.T.Lee, G.A.Whitmore Sizepower: sample size and power calculation in micorarray studies. R package version 1.42.0. [cited 2016 May15]. Available from: www.bioconductor.org/packages/release/bioc/html/sizepower.html
97. H.M.Dionisi, G.Harms, A.C.Layton, et al. Power analysis for real-time PCR quantification of genes in activated sludge and analysis of the variability introduced by DNA extraction. Appl Environ Microbiol. 2003;69:6597–6604.
98. R.R.Kitchen, M.Kubista, A.Tichopad. Statistical aspects of quantitative real-time PCR experiment design. Methods. 2010;50:231–236.
99. S.Hashimoto, W.Qu, B.Ahsan, et al. High resolution analysis of the 5ʹ-end transcriptome using a next generation DNA sequencer. PLoS One. 2009;4:e4108.
100. C.-I.Li, P.-F.Su, Y.Guo, et al. Sample size calculation for differential expression analysis of RNA-seq data under poisson distribution. Int J Comput Biol Drug Des. 2013;6:358–375.
101. J.C.Marioni, C.E.Mason, S.M.Mane, et al. Rnaseq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18:1509–1517.
102. L.Wang, Z.Feng, X.Wang, et al. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26:136–138.
103. J.Li, D.M.Witten, I.M.Johnstone, et al. Normalization, testing, and false discovery rate estimation for rna-sequencing data. Biostatistics. 2011;14:1–16.
104. S.N.Hart, T.M.Therneau, Y.Zhang, et al. Calculating sample size estimates for RNA sequencing data. J Comput Biol. 2013;20:970–978.
105. M.Haznadar, P.Maruvada, E.Mette, et al. Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studies. Metabolomics. 2014;10:176–178.
106. K.A.Stringer, R.T.McKay, A.Karnovsky, et al. metabolomics and its application to acute lung diseases. Front Immunol. 2016;7:44.
107. A.Cavailles, G.Brinchault-Rabin, A.Dixmier, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22:454–475.
108. M.Hardin, E.K.Silverman. Chronic obstructive pulmonary disease genetics: a review of the past and a look into the future. Copd. 2014;1:33–46.
109. P.Kjeldgaard, R.Dahl, A.Løkke, et al. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing? Int J Chron Obstruct Pulmon Dis. 2015;10:407–414.
110. M.M.Ning, E.H.Lo. Opportunities and challenges in omics. Transl Stroke Res. 2010;1:233–237.
111. E.Drucker, K.Krapfenbauer. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. Epma J. 2013;4:7.